Urinary Thromboxane B2 and Lethal Prostate Cancer in African American Men

Area of Science:

• Oncology
• Biochemistry
• Epidemiology

Background:

• Thromboxane A2 (TXA2), a cyclooxygenase-derived eicosanoid, is implicated in cancer metastasis.
• Prostate cancer disproportionately affects African American men, with higher mortality rates.
• Investigating TXA2's role in lethal prostate cancer across racial groups is crucial.

Purpose of the Study:

• To examine the association between TXA2 levels and prostate cancer development and survival.
• To determine if TXA2's role differs between African American and European American men.
• To explore the potential impact of aspirin use on TXA2-related prostate cancer outcomes.

Main Methods:

• Urinary 11-dehydrothromboxane B2 (TXB2), a stable TXA2 metabolite, was measured via mass spectrometry.
• Data from 977 prostate cancer cases and 1022 controls were analyzed using logistic and Cox regression.
• Associations with prostate cancer, metastasis, survival, and aspirin use were assessed, stratified by race.

Main Results:

• Higher urinary TXB2 levels were associated with prostate cancer in African American men (OR=1.50) but not European American men (OR=1.07).
• Elevated TXB2 correlated with metastatic prostate cancer (OR=2.60) and increased all-cause and cancer-specific mortality in African American men.
• Urinary TXB2 showed an inverse association with aspirin use.

Conclusions:

• TXB2 is distinctly associated with prostate cancer outcomes in African American men.
• Upregulated TXA2 synthesis may drive metastasis and lethal disease in this high-risk population.
• Aspirin may prevent lethal prostate cancer by inhibiting TXA2 synthesis.